U-LABA/ICS Effects on Exercise Performance, Vilanterol

• Status: Recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Morten Hostrup, PhD
• Treatments: Fluticasone; Xhance

Criteria

Inclusion Criteria:

• Age 18-39

• Physically active > 5 h weekly

• Maximal oxygen consumption classified as high or very high

Exclusion Criteria:

• Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid

• ECG abnormality

• ACQ score > 1.5

• Severe bronchial hyperreactivity as determined by mannitol test

• FEV1/FVC ratio < 0.7 determined with spirometry

• Chronic illness determined to be a potential risk for participant during study

• In chronic treatment with medication that may interfere with study results

• Pregnancy

• Smoker

• Blood donation during the past 3 months